Stocks in the news: RIL, DHFL, Cipla, Bajaj Consumer, ZEEL and Indiabulls HousingThe USFDA has red-flagged Torrent Pharmaceuticals for significant violations of CGMP.
Stocks in the news: Infosys, IDFC Bank, ONGC, Jet Airways, HDFC and Kotak Mahindra BankHere’s a list of stocks that may hog limelight in today’s session.
Venus Remedies eyes tie-ups for out-licensing drugsVenus Remedies Ltd has targeted a turnover of Rs 1000 crore by FY'18, even as it eyes partners in Europe and US for out licensing drugs.
Venus Remedies gets European patent for antibiotic drugThe product is designed for mixed multi-drug infections for pediatric, geriatric and adult immuno-compromised patients.
Venus gets marketing authorisation from Myanmar for antibioticElores is effective against serious multidrug-resistant hospital-acquired infections involving metallo-beta-lactamase and carbapenem-resist...
Venus eyes Rs 1,000 crore revenue by FY 2017Venus Remedies aims to launch its major products in global markets with an eye on more than doubling revenues to Rs 1,000 cr by 2016-17.
Venus Remedies eyes Rs 1,000 crore revenue by FY'17Drug maker Venus Remedies expects Rs 1,000 crore revenue by FY'17 from the present Rs 460 crore on the back of higher exports.
- Venus Remedies signs deal with Korean co for antibiotic drug
The deal was signed after Companies and Intellectual Property Registration Office (CIPRO) of Republic of South Korea granted the patent to ...
Venus eyes $100 mn from new drug 'Elores' in five yearsVenus Remedies aims to garner around $100 mn in next five years from its new drug that is used for combating spread of bacterial resistance.
- Venus gets US patent for antibiotic product
Venus Remedies has got US patent for Potentox, used for pneumonia other infections and is looking at increasing presence in the $ 12 bn ant...